Emergent versus delayed lithotripsy for obstructing ureteral stones: a cumulative analysis of comparative studies

Objective To analyze the current evidence on the use of ureteroscopy (URS) and extracorporeal shock wave lithotripsy (ESWL) for the management of obstructing ureteral stones in emergent setting. Methods A systematic literature review was performed up to June 2016 using Pubmed and Ovid databases to identify pertinent studies. The PRISMA criteria were followed for article selection. Separate searches were done using a combinations of several search terms: "laser lithotripsy", "ureteroscopy", "extracorporeal shock wave lithotripsy", "ESWL", "rapid", "immediate", "early", "delayed", "late", "ureteral stones", "kidney stones", "renal stones". Only titles related to emergent/rapid/immediate/early (as viably defined in each study) versus delayed/late treatment of ureteral stones with either URS and/or ESWL were considered for screening. Demographics and operative outcomes were compared between emergent and delayed lithotripsy. RevMan review manager software was used to perform data analysis. Results Four studies comparing emergent (n = 526) versus delayed (n = 987) URS and six studies comparing emergent (n = 356) versus delayed (n = 355) SWL were included in the analysis. Emergent URS did not show any significant difference in terms of stone-free rate (91.2 versus 90.9%; OR 1.04; CI 0.71, 1.52; p = 0.84), complication rate (8.7% for emergent versus 11.5% for delayed; OR 0.94; CI 0.65, 1.36; p = 0.74) and need for auxiliary procedures (OR 0.85; CI 0.42, 1.7; p = 0.85) when compared to delayed URS. Emergent ESWL was associated with a higher likelihood of stone free status (OR 2.2; CI 1.55, 3.17; p < 0.001) and a lower likelihood of need for auxiliary maneuvers (OR 0.49; CI 0.33, 0.72; p < 0.001) than the delayed procedure. No differences in complication rates were noticed between the emergent and delayed ESWL (p = 0.37). Conclusions Emergent lithotripsy, either ureteroscopic or extracorporeal, can be offered as an effective and safe treatment for patients with symptomatic ureteral stone. If amenable to ESWL, based on stone and patient characteristics, an emergent approach should be strongly considered. Ureteroscopy in the emergent setting is mostly reserved for distally located stones. The implementation of these therapeutic approaches is likely to be dictated by their availability.info:eu-repo/semantics/publishedVersio

European temporal trends in the use of lymph node dissection in patients with renal cancer

BACKGROUND: The role of lymph node dissection (LND) in renal cell carcinoma (RCC) is still under debate. We aimed to assess the utilization rates of LND over time in Europe. METHODS: A multi-institutional database of 13,581 RCC patients who underwent radical nephrectomy (RN) or nephron sparing surgery (NSS) between 1988 and 2014 was created within an European consortium. We analysed temporal trends in the frequency of LND by using Joinpoint regression. Logistic regression models were used to identify predictors of LND. RESULTS: Overall, 5114 patients (42.7%) underwent LND. Lymph node invasion was recorded in 566 cases (11% of LND patients) which represents 4.7% of the whole study cohort. A gradual decline in the use of LND started in the 1990s. After 2008 LND decreased significantly by 21.5% per year (95%CI -33.3 to -7.5, p < 0.01) until 2011 and stabilized thereafter (Annual Percentage Change 4.9%, 95%CI -3.4 to 13.8, p = 0.2). At multivariable analyses, patient age (OR 0.98, p < 0.0001), type of surgery (RN vs. NSS: OR 5.46, p < 0.0001), surgical approach (open vs. minimally invasive: OR 1.75, p < 0.0001), T stage (T2 vs. T1: OR 1.57; T3-4 vs. T1: OR 1.44, p < 0.0001), clinical tumour size (OR 1.14, p < 0.0001), and year of surgery (OR 0.95, p < 0.0001) were associated with higher probability of LND at nephrectomy. CONCLUSIONS: A trend towards lower LND was observed over time for RCC patients who underwent RN or NSS. LND is more frequently performed in younger patients, locally advanced diseases and in case of open surgery

Photo-vaporisation de la prostate : plaidoyer pour la chirurgie ambulatoire

National audienceObjectifs La photo-vaporisation de la prostate (PVP) est une option thérapeutique de plus en plus répandue dans la chirurgie mini-invasive de l’hypertrophie bénigne de la prostate. Notre objectif était de présenter les résultats de la PVP réalisée en chirurgie ambulatoire comparé à celle réalisée en ambulatoire en début d’expérience. Méthodes Les données pré-, per- et postopératoires de 531 patients opérés par PVP (Greenlight™ AMS, États-Unis) dans deux institutions ont été collectées. Pour chaque opérateur, seuls les patients traités en début d’expérience (moins de 100 procédures) ont été inclus dans l’analyse. Pour comparer les complications postopératoires de la PVP, deux groupes ont été constitués en fonction de leurs modalités d’hospitalisation : groupe 1 (ambulatoire, n = 66) et groupe 2 (hospitalisation, n = 479). Les tests de Student et de Chi2 ont été respectivement utilisés pour comparer les variables continues et catégorielles avec le logiciel IPSS™ (IBM™, États-Unis) version 20. Résultats Les patients opérés en ambulatoire était moins âgés (69 ± 8 vs. 72 ± 9 ans, p = 0,007) et avec moins de comorbidités (ASA : 1,55 ± 0,6 vs. 2,06 ± 0,7 p = 0,001) mais avaient des volumes prostatiques, des débimétrie et scores fonctionnels (IPSS, QdV) similaires. Les durées opératoires sont plus allongées chez les patients hospitalisés (p = 0,001). En revanche, les durée de sondage (p = 0,937), le taux de conversion en monopolaire (p = 0,52), le taux de complications postopératoires (p = 0,32) et le nombre de réintervention (0,97) n’étaient pas statistiquement différents. Conclusion La photo-vaporisation de la prostate est réalisable en chirurgie ambulatoire avec une sécurité suffisante même en début d’expérience. Malgré l’âge avancé et les morbidités compétitives qui constituent des freins à la chirurgie ambulatoire, les patients hospitalisés n’avaient ni plus de complications postopératoires ni plus de réinterventions que les patients opérés en ambulatoir

Neoadjuvant immunotherapy for muscle-invasive bladder cancer

Background and Objectives: Facing neoadjuvant chemotherapy followed by surgery, neoadju-vant immunotherapy is an innovative concept in localized muscle-invasive bladder cancer. Herein, we performed a review of the available and ongoing evidence supporting immune checkpoint in-hibitor (ICI) administration in the early stages of bladder cancer treatment. Materials and Methods: A literature search was performed on Medline and clinical trials databases, using the terms: “bladder cancer” OR “urothelial carcinoma”, AND “neoadjuvant immunotherapy” OR “preoperative im-munotherapy”. We restricted our investigations to prospective clinical trials evaluating anti-PD-(L)1 and anti-CTLA-4 monoclonal antibodies. Data on efficacy, toxicity and potential biomarkers of response were retrieved. Results: The search identified 6 ICIs that were tested in the neoadjuvant setting for localized bladder cancer—4 anti-PD-(L)1 inhibitors (Pembrolizumab, Atezolizumab, Nivolumab and Durvalumab) and 2 anti-CTLA-4 inhibitors (Ipilimumab and Tremelimumab). Most of the existing literature was based on single-arm phase 2 clinical trials that included from 23 to 143 patients. The pathological complete response rate (pCR) and pathological response rate (pRR) ranged from 31% to 46% and from 55.9% to 66%, respectively. Survival data were immature at this time. The safety profile was acceptable, with severe treatment-related adverse events ranging from 6% to 41%. Conclusions: The results of early phase trials are encouraging, and more investigations are needed to strengthen the rationale for immune checkpoint inhibitor administration in localized muscle-invasive bladder cancer